Nebenwirkungen · Votrient
Votrient 200 mg film-coated tablets Votrient 400 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 13–14
HOS-122599 · Präparat HOS-095539
13 Very common Diarrhoea 614 (53%_) 65 (6%) 2 (<1%) Nausea 386 (34%) 14 (1%) 0 Vomiting 225 (20%) 18 (2%) 1 (<1%) Abdominal paina 139 (12%) 15 (1%) 0 Common Stomatitis 96 (8%) 4 (<1%) 0 Dyspepsia 83 (7%) 2 (<1%) 0 Flatulence 43 (4%) 0 0 Abdominal distension 36 (3%) 2 (<1%) 0 Mouth ulceration 28 (2%) 3 (<1%) 0 Dry mouth 27 (2%) 0 0 Uncommon Pancreatitis 8 (<1%) 4 (<1%) 0 Rectal haemorrhage 8 (<1%) 2 (<1%) 0 Haematochezia 6 (<1%) 0 0 Gastrointestinal 4 (<1%) 2 (<1%) 0 haemorrhage Melaena 4 (<1%) 1(<1%) 0 Gastrointestinal Frequent bowel 3 (<1%) 0 0 disorders movements Anal haemorrhage 2 (<1%) 0 0 Large intestine 2 (<1%) 1 (<1%) 0 perforation Mouth haemorrhage 2 (<1%) 0 0 Upper gastrointestinal 2 (<1%) 1 (<1%) 0 haemorrhage Enterocutaneous 1 (<1%) 0 0 fistula Haematemesis 1 (<1%) 0 0 Haemorrhoidal 1 (<1%) 0 0 haemorrhage Ileal perforation 1 (<1%) 0 1 (<1%) Oesophageal 1 (<1%) 0 0 haemorrhage Retroperitoneal 1 (<1%) 0 0 haemorrhage Common Hyperbilirubinaemia 38 (3%) 2 (<1%) 1 (<1%) Hepatic function 29 (3%) 13 (1%) 2 (<1%) abnormal Hepatobiliary Hepatotoxicity 18 (2%) 11(<1%) 2 (<1%) disorders Uncommon Jaundice 3 (<1%) 1 (<1%) 0 Drug induced liver 2 (<1%) 2 (<1%) 0 injury Hepatic failure† 1 (<1%) 0 1 (<1%)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-28T11:24:00Z · SHA-256 38e00132fe316301c56a9c9a4f9247483c54b55dd743bedaab120a272380aaff · Passage f9475a0c689cd6ab1570f427c410f17513dc309f8e4cc71d94f281cb19fc06ea · Zeichen 9288–12425 im Abschnitt